@jobo
Hmmm…the fact that the trial is in phase 3 indicates that it may be a promising trial.
The drug is Elahere with Beva for platinum-sensitive participants with FRa expression.
Elahere is currently in approval process for platinum-resistant use.
This sounds like something I would definitely discuss with my Onc if I were eligible. I haven't done extensive research on Elahere for platinum-sensitive…but, the fact that it is in Phase 3 sounds like they may be having some success with this combo and it is being conducted in many locations.
-------------------------------------------